For visse ikke- selektive NSAID, herunder piroxicam, blev der imidlertid fundet at være behov for en nærmere vurdering af risk/ benefit- forholdet.
However a need to further evaluate the benefit/ risk balance of some non-selective NSAIDs including piroxicam was identified.